PA8441401A1 - Procedimiento para piridinas sustituidas - Google Patents

Procedimiento para piridinas sustituidas

Info

Publication number
PA8441401A1
PA8441401A1 PA19978441401A PA8441401A PA8441401A1 PA 8441401 A1 PA8441401 A1 PA 8441401A1 PA 19978441401 A PA19978441401 A PA 19978441401A PA 8441401 A PA8441401 A PA 8441401A PA 8441401 A1 PA8441401 A1 PA 8441401A1
Authority
PA
Panama
Prior art keywords
procedure
amino
piridines
substituted
formula
Prior art date
Application number
PA19978441401A
Other languages
English (en)
Spanish (es)
Inventor
Robert Lee Dow
Keith Michael Devries
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8441401A1 publication Critical patent/PA8441401A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PA19978441401A 1996-11-14 1997-11-12 Procedimiento para piridinas sustituidas PA8441401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
PA8441401A1 true PA8441401A1 (es) 2000-05-24

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978441401A PA8441401A1 (es) 1996-11-14 1997-11-12 Procedimiento para piridinas sustituidas

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00020.png)
EP (1) EP0938476B1 (US06291489-20010918-C00020.png)
JP (1) JP3510635B2 (US06291489-20010918-C00020.png)
KR (1) KR20000053314A (US06291489-20010918-C00020.png)
CN (1) CN1237160A (US06291489-20010918-C00020.png)
AP (1) AP805A (US06291489-20010918-C00020.png)
AR (1) AR010584A1 (US06291489-20010918-C00020.png)
AT (1) ATE319687T1 (US06291489-20010918-C00020.png)
AU (1) AU4634697A (US06291489-20010918-C00020.png)
BG (1) BG103393A (US06291489-20010918-C00020.png)
BR (1) BR9712951A (US06291489-20010918-C00020.png)
CA (1) CA2270386C (US06291489-20010918-C00020.png)
CO (1) CO4930261A1 (US06291489-20010918-C00020.png)
DE (1) DE69735433D1 (US06291489-20010918-C00020.png)
EA (1) EA199900375A1 (US06291489-20010918-C00020.png)
GT (1) GT199700118A (US06291489-20010918-C00020.png)
HR (1) HRP970612A2 (US06291489-20010918-C00020.png)
ID (1) ID18898A (US06291489-20010918-C00020.png)
IL (1) IL129688A0 (US06291489-20010918-C00020.png)
IS (1) IS5029A (US06291489-20010918-C00020.png)
MA (1) MA24401A1 (US06291489-20010918-C00020.png)
MY (1) MY132507A (US06291489-20010918-C00020.png)
NO (1) NO992296L (US06291489-20010918-C00020.png)
OA (1) OA11044A (US06291489-20010918-C00020.png)
PA (1) PA8441401A1 (US06291489-20010918-C00020.png)
PE (1) PE10299A1 (US06291489-20010918-C00020.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00020.png)
TR (1) TR199901063T2 (US06291489-20010918-C00020.png)
UY (1) UY24774A1 (US06291489-20010918-C00020.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00020.png)
YU (1) YU22099A (US06291489-20010918-C00020.png)
ZA (1) ZA9710186B (US06291489-20010918-C00020.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909555A (pt) * 1998-04-08 2000-12-19 Novartis Ag Novartis S A Novar Herbicidas
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
EP1454899A1 (en) * 2001-10-17 2004-09-08 Kaneka Corporation Process for preparation of (s)-alpha-halome thylpyridine methanol derivatives
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
MXPA04008298A (es) * 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
WO2004099189A1 (en) 2003-05-09 2004-11-18 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220399A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
EP0828712A1 (en) * 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists

Also Published As

Publication number Publication date
HRP970612A2 (en) 1998-08-31
CA2270386A1 (en) 1998-05-22
BR9712951A (pt) 1999-12-07
EA199900375A1 (ru) 1999-12-29
MA24401A1 (fr) 1998-07-01
BG103393A (en) 2000-07-31
TR199901063T2 (xx) 1999-08-23
DE69735433D1 (de) 2006-05-04
JP3510635B2 (ja) 2004-03-29
CN1237160A (zh) 1999-12-01
AU4634697A (en) 1998-06-03
GT199700118A (es) 1999-05-05
AP9701147A0 (en) 1998-01-31
US6291489B1 (en) 2001-09-18
NO992296D0 (no) 1999-05-12
MY132507A (en) 2007-10-31
CO4930261A1 (es) 2000-06-27
CA2270386C (en) 2004-08-03
KR20000053314A (ko) 2000-08-25
ID18898A (id) 1998-05-20
EP0938476A1 (en) 1999-09-01
OA11044A (en) 2002-02-20
YU22099A (sh) 2001-09-28
JP2000504347A (ja) 2000-04-11
AP805A (en) 2000-01-28
NO992296L (no) 1999-05-12
IS5029A (is) 1999-04-16
AR010584A1 (es) 2000-06-28
WO1998021184A1 (en) 1998-05-22
EP0938476B1 (en) 2006-03-08
ZA9710186B (en) 1999-05-12
TNSN97172A1 (fr) 2005-03-15
ATE319687T1 (de) 2006-03-15
PE10299A1 (es) 1999-02-10
IL129688A0 (en) 2000-02-29
UY24774A1 (es) 1998-05-05

Similar Documents

Publication Publication Date Title
PA8441401A1 (es) Procedimiento para piridinas sustituidas
PA8521701A1 (es) Derivados de pirazol
PT83713B (pt) Processo para a preparacao de derivados de 4-benzil-1-(2h)-ftalazinona e de composicoes farmaceuticas que os contem
BR9304185A (pt) Método para a utilização de um selante de fibrina, método para a preparação de ume composição que compreende monõmero de fibrina a partir de fibrinogénio, composição aquosa, composição, kit e suporte sólido
AR003401A1 (es) Procedimiento para la peparacion de sildenafil y compuestos intermediarios para dicho procedimiento
RS50437B (sr) Benzoilpirazoli i njihova primena u ulozi herbicida
ES2163512T3 (es) Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.
ES2175244T3 (es) Empleo de acido poliasparaginico y de sus sales.
CO4950531A1 (es) Analogos de la vitamina d3 composciiones farmaceuticas que los contienen
ES2143734T3 (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
FI943508A (fi) Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
YU19997A (sh) Analozi fluorovanog vitamina d3
BR9709570A (pt) Melhoramentos no efeito de herbicidas
ES2096344T3 (es) Sulfonilureas herbicidas, procedimiento para su obtencion y su empleo.
PT93518A (pt) <{(1,3,5-triazin-2-il)-aminocarbonil}-amonossulfunil>- benzoico e de composicoes herbicidas que os contem
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
GT199900113A (es) Inhibidores de las fkbp.
ES2076037T3 (es) Aminoesteres de los acidos 1,3,5-triacin-2,4,6-tris-alquilaminocarboxilicos, agentes biocidas que los contienen, asi como procedimiento para su fabricacion.
BR0211425A (pt) Método para a preparação de compostos, e, uso de uma composição
ES2114115T3 (es) Procedimiento y nuevos productos intermedios para la obtencion de triazolinonas.
SV1999000075A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetil)-cefemos
PE36098A1 (es) Nuevas heteroariloxazolidinonas
ES2155187T3 (es) Antagonistas biciclicos de taquicinas, preparacion de estos antagonistas y su utilizacion en compuestos farmaceuticos.
BR9408078A (pt) Composto composição herbicida e processo para controlar vegetação indesejável
ECSP972312A (es) Procedimiento para piridinas sustituidas